AEON Biopharma, Inc. AEON

AEON Company Overview

AEON Biopharma, Inc. is a U.S.-based clinical-stage biotechnology company focused on the development of botulinum toxin therapeutics for debilitating medical conditions. The company operates within the biotechnology and specialty pharmaceuticals industries, with an emphasis on neurology and related therapeutic indications. AEON’s primary asset is ABP-450, a proprietary formulation of botulinum toxin type A that has been evaluated for both therapeutic and aesthetic applications. The company’s business model centers on clinical development, regulatory advancement, and eventual commercialization through strategic partnerships and licensing arrangements.

AEON traces its origins to the licensing and development of botulinum toxin technology intended to compete within established neurotoxin markets dominated by larger pharmaceutical companies. The company became publicly traded through a merger with a special purpose acquisition company in 2023, after previously operating as a privately held biotechnology enterprise. AEON has positioned itself around expanding the use of botulinum toxin therapies into chronic neurological and pain-related conditions, particularly migraine-related disorders, where long-duration efficacy and differentiated treatment protocols may provide competitive advantages.